New lung cancer pill cuts the risk of death by 44% in a trial
A new lung cancer pill, divarasib, beat two approved drugs in a trial. It cut the risk of death by 44% for patients with a gene change called KRAS G12C. Patients lived a median of 17.7 months, against 12 on older drugs. Researcher Ferdinandos Skoulidis called it "a new standard of care."
Where this came from. 2 outlets reported this. We read them, then wrote the sixty words above.